Selexis, a JSR Life Sciences company in cell line development with best-in-class modular technology and highly specialized solutions, and Generium, a Russian pharmaceutical biotechnology company, has launched Generium’s biosimilar – omalizumab (Genolar) for treating persistent atopic bronchial asthma and resistant chronic idiopathic urticaria. Genolar is a recombinant humanized IgG1k monoclonal antibody that binds to free human immunoglobulin E (IgE) and is used to improve the control of persistent asthma caused by allergy. It could be useful for children with uncontrolled asthma after glucocorticosteroids inhalation.